Diagnostická, prognostická a prediktivní imunohistochemie při maligním melanomu kůže


Autoři: Roncati Luca
Působiště autorů: Department of Diagnostic and Clinical Medicine and of Public Health, Institute of Pathology, University of Modena and Reggio Emilia, Modena, Italy
Vyšlo v časopise: Klin Onkol 2018; 31(2): 152-155
Kategorie: Aktuality v onkologii
doi: 10.14735/amko2018152

Souhrn

Autor deklaruje, že v souvislosti s předmětem studie nemá žádné komerční zájmy.

Redakční rada potvrzuje, že rukopis práce splnil ICMJE kritéria pro publikace zasílané do biomedicínských časopisů.

Obdrženo:
25. 12. 2017

Přijato:
4. 1. 2018


Zdroje

1. Roncati L, Piscioli F, Pusiol T et al. Microinvasive radial growth phase of cutaneous melanoma: a histopathological and immunohistochemical study with diagnostic implications. Acta Dermatovenerol Croat 2017; 25 (1): 39–45.

2. Coons AH, Creech HJ, Jones RN. Immunological properties of an antibody containing a fluorescent group. Proc Soc Exp Biol Med 1941; 47: 200–202.

3. Roncati L, Manenti A, Sighinolfi P. Immunohistochemi-cal improvement in the analysis of the lymphatic metastases from lung carcinoma. Ann Thorac Surg 2014; 97 (1): 380–381. doi: 10.1016/j.athoracsur.2013.06.072.

4. Marenholz I, Heizmann CW, Fritz G. S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature). Biochem Biophys Res Commun 2004; 322 (4): 1111–1122. doi: 10.1016/j.bbrc.2004.07.096.

5. Donato R. Intracellular and extracellular roles of S100 proteins. Microsc Res Tech 2003; 60 (6): 540–551. doi: 10.1002/jemt.10296.

6. Nonaka D, Chiriboga L, Rubin BP. Differential expression of S100 protein subtypes in malignant melanoma, and benign and malignant peripheral nerve sheath tumors. J Cutan Pathol 2008; 35 (11): 1014–1019. doi: 10.1111/j.1600-0560.2007.00953.x.

7. Bioley G, Jandus C, Tuyaerts S et al. Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers. J Immunol 2006; 177 (10): 6769–6779. doi: 10.1111/j.1600-0560.2007.00953.x.

8. Du J, Miller AJ, Widlund HR et al. MLANA/MART1 and SILV/PMEL17/GP100 are transcriptionally regulated by MITF in melanocytes and melanoma. Am J Pathol 2003; 163 (1): 333–343. doi: 10.1016/S0002-9440 (10) 63657-7.

9. Léger S, Balguerie X, Goldenberg A et al. Novel and recurrent non-truncating mutations of the MITF basic domain: genotypic and phenotypic variations in Waardenburg and Tietz syndromes. Eur J Hum Genet 2012; 20 (5): 584–587. doi: 10.1038/ejhg.2011.234.

10. Hershey CL, Fisher DE. Mitf and Tfe3: members of a b-HLH-ZIP transcription factor family essential for osteoclast development and function. Bone 2004; 34 (4): 689–696. doi: 10.1016/j.bone.2003.08.014.

11. Tudrej KB, Czepielewska E, Kozłowska-Wojciechowska M. SOX10-MITF pathway activity in melanoma cells. Arch Med Sci 2017; 13 (6): 1493–1503. doi: 10.5114/aoms. 2016.60655.

12. Wasmeier C, Hume AN, Bolasco G et al. Melanosomes at a glance. J Cell Sci 2008; 121 (24): 3995–3999. doi: 10.1242/jcs.040667.

13. Kapur RP, Bigler SA, Skelly M et al. Anti-melanoma monoclonal antibody HMB45 identifies an oncofetal glycoconjugate associated with immature melanosomes. J Histochem Cytochem 1992; 40 (2): 207–212. doi: 10.1177/40.2.1552165.

14. Clarkson KS, Sturdgess IC, Molyneux AJ. The usefulness of tyrosinase in the immunohistochemical assessment of melanocytic lesions: a comparison of the novel T311 antibody (anti-tyrosinase) with S-100, HMB45, and A103 (anti-melan-A). J Clin Pathol 2001; 54 (3): 196–200.

15. Roncati L, Piscioli F, Pusiol T. The significance of regression in thin melanoma of the skin. Ir J Med Sci 2017; 187 (1): 95–96. doi: 10.1007/s11845-017-1612-1.

16. Roncati L, Vergari B, Del Gaudio A. The ‚all-or-none law‘ applied to the vertical growth phase of cutaneous malignant melanoma. Chonnam Med J 2017; 53 (3): 234–235. doi: 10.4068/cmj.2017.53.3.234.

17. Roncati L, Pusiol T, Piscioli F. Prognostic predictors of thin melanoma in clinico-pathological practice. Acta Dermatovenerol Croat 2017; 25 (2): 159–160.

18. Roncati L, Piscioli F, Pusiol T. Clinical application of the unifying concept of cutaneous melanoma. Chonnam Med J 2017; 53 (1): 78–80. doi: 10.4068/cmj.2017.53.1.78.

19. Piscioli F, Pusiol T, Roncati L. Wisely choosing thin melanomas for sentinel lymph node biopsy. J Am Acad Dermatol 2017; 76 (1): e25. doi: 10.1016/j.jaad.2016.08.069.

20. Roncati L, Piscioli F, Pusiol T. SAMPUS, MELTUMP and THIMUMP – Diagnostic categories characterized by uncertain biological behavior. Klin Onkol 2017; 30 (3): 221–223. doi: 10.14735/amko2017221.

21. Piscioli F, Pusiol T, Roncati L. Histopathological determination of thin melanomas at risk for metastasis. Melanoma Res 2016; 26 (6): 635. doi: 10.1097/CMR.000 0000000000288.

22. Piscioli F, Pusiol T, Roncati L. Nowadays a histological sub-typing of thin melanoma is demanded for a proper patient management. J Plast Reconstr Aesthet Surg 2016; 69 (11): 1563–1564. doi: 10.1016/j.bjps.2016.08.026.

23. Pusiol T, Piscioli F, Speziali L et al. Clinical features, dermoscopic patterns, and histological diagnostic model for melanocytic tumors of uncertain malignant potential (MELTUMP). Acta Dermatovenerol Croat 2015; 23 (3): 185–194.

24. Piscioli F, Pusiol T, Roncati L. Thin melanoma subtyping fits well with the American Joint Committee on Cancer staging system. Melanoma Res 2016; 26 (6): 636. doi: 10.1097/CMR.0000000000000301.

25. Piscioli F, Pusiol T, Roncati L. Critical points of T1 stage in primary melanoma. Melanoma Res 2017; 27 (4): 399. doi: 10.1097/CMR.0000000000000357.

26. Roncati L, Pusiol T, Piscioli F. Up-to-date proposal for a histologic subcategorization of thin melanomas. Adv Anat Pathol 2017. doi: 10.1097/PAP.0000000000000148.

27. Roncati L, Piscioli F, Pusiol T. The importance of mitotic rate reporting in primary cutaneous melanoma. J Surg Oncol 2017; 116 (7): 958–959. doi: 10.1002/jso.24738.

28. Roncati L, Piscioli F, Pusiol T. Surgical outcomes reflect the histological types of cutaneous malignant melanoma. J Eur Acad Dermatol Venereol 2017; 31 (6): e279–e280. doi: 10.1111/jdv.14023.

29. Roncati L, Piscioli F, Pusiol T. Sentinel lymph node in thin and thick melanoma. Klin Onkol 2016; 29 (5): 393–394.

30. Roncati L, Piscioli F, Pusiol T. Current controversies on sentinel node biopsy in thin and thick cutaneous melanoma. Eur J Surg Oncol 2017; 43 (2): 506–507. doi: 10.1016/j.ejso.2016.09.014.

31. Roncati L, Manenti A, Piscioli F et al. The immune score as a further prognostic indicator in carcinoid tumors. Chest 2017; 151 (5): 1186. doi: 10.1016/j.chest.2016.10. 032.

32. Roncati L, Manenti A, Piscioli F et al. Immunoscoring the lymphocytic infiltration in carcinoid tumours. Histopathology 2017; 70 (7): 1175–1177. doi: 10.1111/his.13168.

33. Roncati L, Manenti A, Farinetti A et al. The association between tumor-infiltrating lymphocytes (TILs) and metastatic course in neuroendocrine neoplasms. Surgery 2016; 160 (6): 1709. doi: 10.1016/j.surg.2015.12.030.

34. Roncati L, Barbolini G, Piacentini F et al. Prognostic factors for breast cancer: an immunomorphological update. Pathol Oncol Res 2016; 22 (3): 449–452. doi: 10.1007/s12253-015-0024-7.

35. Piscioli F, Pusiol T, Roncati L. Diagnostic disputes regarding atypical melanocytic lesions can be solved by using the term MELTUMP. Turk Patoloji Derg 2016; 32 (1): 63–64. doi: 10.5146/tjpath.2015.01330.

36. Piscioli F, Pusiol T, Roncati L. Diagnostic approach to melanocytic lesion of unknown malignant potential. Melanoma Res 2016; 26 (1): 91–92. doi: 10.1097/CMR.000 0000000000215.

37. Roncati L, Barbolini G, Sartori G et al. Loss of CDKN2A promoter methylation coincides with the epigenetic transdifferentiation of uterine myosarcomatous cells. Int J Gynecol Pathol 2016; 35 (4): 309–315. doi: 10.1097/PGP. 0000000000000181.

38. Zhang D, Zhu R, Zhang H et al. MGDB: a comprehensive database of genes involved in melanoma. Database (Oxford) 2015; 2015: pii: bav097. doi: 10.1093/database/bav097.

39. Lovly CM, Dahlman KB, Fohn LE et al. Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. PLoS One 2012; 7 (4): e35309. doi: 10.1371/journal.pone.0035309.

40. Wong DJ, Ribas A. Targeted therapy for melanoma. Cancer Treat Res 2016; 167: 251–262. doi: 10.1007/978-3-319-22539-5_10.

41. Lulli D, Carbone ML, Pastore S. The MEK inhibitors trametinib and cobimetinib induce a type I interferon response in human keratinocytes. Int J Mol Sci 2017; 18 (10). doi: 10.3390/ijms18102227.

42. Queirolo P, Spagnolo F. Binimetinib for the treatment of NRAS-mutant melanoma. Expert Rev Anticancer Ther 2017; 17 (11): 985–990. doi: 10.1080/1473 7140.2017.1374177.

43. Costa R, Costa RB, Talamantes SM et al. Meta-analysis of selected toxicity endpoints of CDK4/6 inhibitors: palbociclib and ribociclib. Breast 2017; 35: 1–7. doi: 10.1016/j.breast.2017.05.016.

44. Roncati L, Barbolini G, Gatti AM et al. The uncontrolled sialylation is related to chemoresistant metastatic breast cancer. Pathol Oncol Res 2016; 22 (4): 869–873. doi: 10.1007/s12253-016-0057-6.

45. Murer C, Kränzlin-Stieger P, French LE et al Successful treatment with imatinib after nilotinib and ipilimumab in a c-kit-mutated advanced melanoma patient: a case report. Melanoma Res 2017; 27 (4): 396–398. doi: 10.1097/ CMR.0000000000000358.

46. Najem A, Krayem M, Perdrix A et al. New drug combination strategies in melanoma: current status and future directions. Anticancer Res 2017; 37 (11): 5941–5953. doi: 10.21873/anticanres.12041.

47. Karlsson AK, Saleh SN. Checkpoint inhibitors for malignant melanoma: a systematic review and meta-analysis. Clin Cosmet Investig Dermatol 2017; 10: 325–339. doi: 10.2147/CCID.S120877.

48. Walunas TL, Lenschow DJ, Bakker CY et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994; 1 (5): 405–413.

49. Letendre P, Monga V, Milhem M et al. Ipilimumab: from preclinical development to future clinical perspectives in melanoma. Future Oncol 2017; 13 (7): 625–636. doi: 10.2217/fon-2016-0385.

50. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 2010; 236: 219–242. doi: 10.1111/j.1600-065X.2010.00923.x.

51. Wang X, Teng F, Kong L et al. PD-L1 expression in human cancers and its association with clinical outcomes. Onco Targets Ther 2016; 9: 5023–5039. doi: 10.2147/OTT.S105862.

52. Prasad V, Kaestner V. Nivolumab and pembrolizumab: monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable. Semin Oncol 2017; 44 (2): 132–135. doi: 10.1053/j.seminoncol.2017. 06.007.

53. Syn NL, Teng MWL, Mok TSK et al. De-novo and acquired resistance to immune checkpoint targeting. Lancet Oncol 2017; 18 (12): e731–e741. doi: 10.1016/ S1470-2045 (17) 30607-1.

54. Kubeček O, Kopecký J. Microsatellite instability in melanoma: a comprehensive review. Melanoma Res 2016; 26 (6): 545–550. doi: 10.1097/CMR.0000000000000298.

55. Kim ST, Klempner SJ, Park SH et al. Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy. Oncotarget 2017; 8 (44): 77415–77423. doi: 10.18632/oncotarget.20 492.

56. Kubecek O, Trojanova P, Molnarova V et al. Microsatellite instability as a predictive factor for immunotherapy in malignant melanoma. Med Hypotheses 2016; 93: 74–76. doi: 10.1016/j.mehy.2016.05.023.

57. Roncati L, Manenti A, Pusiol T et al. Testosterone aromatization to estradiol in course of ovarian functioning Brenner tumor associated with endometrial carcinoma and endometriosis (Roncati-Manenti triad). Int J Gynecol Cancer 2016; 26 (8): 1461–1464. doi: 10.1097/IGC.0000000000000779.

Štítky
Dětská onkologie Chirurgie všeobecná Onkologie

Článek vyšel v časopise

Klinická onkologie

Číslo 2

2018 Číslo 2

Nejčtenější v tomto čísle

Tomuto tématu se dále věnují…


Kurzy

Zvyšte si kvalifikaci online z pohodlí domova

Léčba bolesti v ordinaci praktického lékaře
nový kurz
Autoři: MUDr. PhDr. Zdeňka Nováková, Ph.D.

Revmatoidní artritida: včas a k cíli
Autoři: MUDr. Heřman Mann

Jistoty a nástrahy antikoagulační léčby aneb kardiolog - neurolog - farmakolog - nefrolog - právník diskutují
Autoři: doc. MUDr. Štěpán Havránek, Ph.D., prof. MUDr. Roman Herzig, Ph.D., doc. MUDr. Karel Urbánek, Ph.D., prim. MUDr. Jan Vachek, MUDr. et Mgr. Jolana Těšínová, Ph.D.

Léčba akutní pooperační bolesti
Autoři: doc. MUDr. Jiří Málek, CSc.

Nové antipsychotikum kariprazin v léčbě schizofrenie
Autoři: prof. MUDr. Cyril Höschl, DrSc., FRCPsych.

Všechny kurzy
Kurzy Doporučená témata Časopisy
Přihlášení
Zapomenuté heslo

Nemáte účet?  Registrujte se

Zapomenuté heslo

Zadejte e-mailovou adresu se kterou jste vytvářel(a) účet, budou Vám na ni zaslány informace k nastavení nového hesla.

Přihlášení

Nemáte účet?  Registrujte se